Haluk PhD's Email Addresses & Phone Numbers

Innovative cancer biologist with successful expertise in target identification, validation and signal transduction as well as cancer immunotherapy with extensive preclinical pharmacology models of human cancer. Established core facility of Patient Derived Xenograft of human breast cancer at Dana Farber Cancer Institute. Expertise in conducting in vivo and ex vivo experiments on animal models and PDX models...

Innovative cancer biologist with successful expertise in target identification, validation and signal transduction as well as cancer immunotherapy with extensive preclinical pharmacology models of human cancer. Established core facility of Patient Derived Xenograft of human breast cancer at Dana Farber Cancer Institute. Expertise in conducting in vivo and ex vivo experiments on animal models and PDX models of cancer, delivery of candidate targeted drug regimens. Trained in oncology over 10 years in world-renowned laboratories. Skilled with project leadership, international collaborations, teamwork, supervision of technician level scientists and multi-tasking abilities. Specialties: Cancer biology, signaling in cancer, target identification & validation using viral screening, ,chromatin biology, biomarker discovery, genome editing, Targeted therapy, translational research, animal models of cancer (PDX and GEMM) as well as imaging.Research Fellow @ • Developed genetically engineered mice models to study the roles of PI3K isoforms in Pten deficient leukemia and study PI3K in mouse model of colorectal cancer. • Identified PI3K isoform dependence as a modulator of CXCL12/CXCR4 signaling in myeloid neoplasia. Established Patient Derived Xenograft (PDX) models of breast cancer and established a core facilty of PDX at Dana Farber Cancer Institute. • Executed pooled Tel-Receptor Tyrosine Kinase retrovirus screening in Ba/F3 cells to identify Pten synthetic lethality in Leukemia. • Discovered a kinase as a vulnerability for Pten deficient cancer cells. • Developing genome editing tools to target and validate novel oncogenes. • Developing techniques for ex vivo expansion of Hematopoietic stem cells. From October 2010 to Present (5 years 3 months) senior research scientist @ From 2010 to 2015 (5 years) PhD Student @ • Developed RNAi screening to identify aberrant epigenetic mechanisms contributing to liver cancer. • Developed and characterized new monoclonal antibodies for malignant forms of Beta-catenin. From September 2007 to September 2010 (3 years 1 month) Visiting Scientist @ • Developed RNAi screening to identify aberrant epigenetic mechanisms contributing to liver cancer. • Developed and characterized new monoclonal antibodies for malignant forms of Beta-catenin. From September 2007 to July 2010 (2 years 11 months) graduate students @ • Used RNAi screening and GWAS data to find novel genetic and epigenetic targets in Liver Cancer. • Identified and characterized ATAD2 gene as an oncogene in hepatocellular carcinoma. • Discovered Canonical Wnt/Beta-Catenin signaling is repressed by non-canonical Wnt/Beta-Catenin signaling in hepatocellular carcinoma cells. • Discovered several genes in signal transduction and senescence pathways using siRNA screening From 2004 to 2010 (6 years) Doctor of Philosophy (PhD), Molecular Biology and Genetics @ Bilkent University From 2004 to 2010 Bachelor of Science (BSc), Molecular Biology and Genetics @ Boğaziçi Üniversitesi / Bogazici University From 1999 to 2004 Haluk PhD is skilled in: Cancer, Cell Culture, Signal Transduction, Animal Models, Molecular Biology, Cell Biology, Targeted Therapies, Cancer Immunotherapy, Cancer Research, Western Blotting, Flow Cytometry, RNAi, Genetics, Transfection, PCR